News

The partnership will offer specialty physician practices across retina and other specialties access to SamaCare's platform.

According to a team of researchers at UCLA, the “dormant” cone photoreceptors might actually continue to drive retinal activity for vision.

The FDA has approved enrolling pediatric patients in the ongoing OCU400 Phase 1/2 trial who have: 1) RP associated with NR2E3 and RHO mutations and 2) LCA associated with CEP290 gene mutations.

According to the company, UBX1325 monotherapy did not achieve non-inferiority through 24 weeks due, in part, to an unexpected 3.5 letter gain in the anti-VEGF control arm.

The various aspects of home monitoring for patients with age-related macular degeneration are discussed in this point/counterpoint by Prof. Rufino Silva, University of Coimbra / Coimbra Hospital and University Centre, Portugal, and Univ.-Prof. Dr. med. Robert P. Finger, PhD, Department of Ophthalmology, University of Bonn, Germany, during the 14th annual Congress on Controversies in Ophthalmology in Lisbon, Portugal.

The company is advancing AAV-based gene therapy candidates toward IND studies on encouraging animal proof of concept data in Stargardt disease, X-linked retinoschisis and autosomal dominant optic atrophy.

Pedro Fonseca, MD, Coimbra Hospital and University Centre, Portugal, and Andrew G. Lee, MD, Blanton Eye Institute, Houston Methodist, Texas, USA, discuss the various pros and cons of offering teprotumumab for all patients with thyroid eye disease.

According to researchers at the Max Planck Institute, the Kynurenine pathway is not only important for eye pigment formation, it also plays a role in maintaining retinal health.

In a keynote lecture at the 14th Annual Congress on Controversies in Ophthalmology in Lisbon, Hendrik Scholl, MD, co-founder and director of the Institute of Molecular and Clinical Ophthalmology Basel, discussed its mission to unravel the mysteries of vision and human eye disease.

Angela Carneiro, MD, PhD, discusses her position on a discussion titled Presence of Macular Neovascularization on OCTA is Predictive of Subsequent Exudation with David Hutton, Executive Editor, Ophthalmology Times®.

Antonio Campos, MD, PhD, discusses his position on a discussion titled Durability Associated with Multi-target Therapies is Superior to anti-VEGF Mono-target Therapy in AMD with David Hutton, Executive Editor, Ophthalmology Times.®

According to researchers, diabetes mellitus is caused by higher levels of blood glucose due to the lack of production of insulin by the body, resistance to insulin, or both.

Maternal pregnancy-related smoking was measured using key metrics: Provider or self-reported smoking during pregnancy and cotinine and hydroxycotinine in neonatal blood.

Researchers are using a new, highly versatile form of CRISPR-based genome editing with the potential to correct a wide variety of disease-causing genetic mutations.

The sharing of data between ophthalmologists and optometrists ultimately can lead to earlier diagnosis and better results for patients.

PBM treatment showed a statistically significant slowing of disease progression in patients with early to intermediate dry AMD.

To support congressional action, 135 health organizations – including the American Academy of Ophthalmology – sent a letter to congressional leaders pointing out that a full inflation-based update is the primary solution to the ongoing problem with the Medicare Physician Fee Schedule.

Imaging biomarkers are useful to determine the degree of EZ attenuation in the fovea.

Delegates will analyze the most relevant and controversial issues within the field of ophthalmology at this year’s congress in Lisbon, Portugal, from March 24 to 25.

Industry leaders look at what’s in the therapeutic delivery pipeline for these disorders.

The results support plan to advance lead program in ABCA4-related retinopathies into the clinic in 2024 and expansion into other ophthalmology indications.

Physicians should consider hydrodynamic cavitation when performing this procedure.

According to a University of Florida Health, the researchers used gene therapy to both knock down and replace malfunctioning genetic material that affects light-sensing photoreceptors in the retina.

Examining an intraocular implant that can sharpen vision for patients as disease progresses.

According to the company, the funding supports the Phase 2 clinical study of ONL1204 ophthalmic solution to evaluate the safety and efficacy in patients diagnosed with macula-off rhegmatogenous retinal detachment.

For this study, researchers focused on photoreceptor cells (PRCs), which are light-detecting cells found in the retina.

According to the company, post-hoc time-to-event analysis signals up to 59% risk reduction in rate of vision loss compared to sham treatment at 12 months. The analysis will be presented at the ARVO Annual Meeting from April 23-27 in New Orleans.

The company’s therapeutic is a single therapy for multiple forms of age-related macular degeneration. NM3086 is a highly potent alternative pathway (AP) blocker that does not affect the classical pathway.

There are now treatments available that target VEGF to prevent vessel overgrowth, and they often provide dramatic benefits at first. Unfortunately, these benefits can fade with time.